Semaglutide Offers Better Value per Diabetes Patient Treated Than Exenatide or Dulaglutide
Once-weekly semaglutide gets more type 2 diabetes patients to blood sugar and weight loss targets per dollar spent than exenatide ER or dulaglutide in the US market.
Quick Facts
What This Study Found
Once-weekly semaglutide (0.5 mg and 1.0 mg) offered superior cost-per-outcome versus exenatide extended-release and dulaglutide for type 2 diabetes. Semaglutide was the most effective at getting patients to all three treatment targets: HbA1c below 7.0%, HbA1c below 7.0% without hypoglycemia or weight gain, and a combined target of ≥1.0% HbA1c reduction with ≥5.0% weight loss.
Critically, the cost-to-efficacy ratio also favored semaglutide — meaning it wasn't just more effective, but more cost-effective per patient who reached treatment goals. This held true for both the simple glycemic target and the more demanding composite endpoints.
Key Numbers
Semaglutide 0.5 mg and 1.0 mg vs exenatide ER and dulaglutide · 3 endpoints assessed · superior efficacy-to-cost ratio across all endpoints · US wholesale acquisition costs (July 2018)
How They Did This
Post-hoc economic analysis using efficacy data from the SUSTAIN 3 (semaglutide vs exenatide ER) and SUSTAIN 7 (semaglutide vs dulaglutide) randomized trials. Researchers calculated the proportion of patients reaching three clinical targets, then combined these with annual US treatment costs to generate cost-of-control ratios plotted on a cost-efficacy plane.
Why This Research Matters
GLP-1 drugs are expensive, and payers (insurance companies, employers, governments) need to know which ones deliver the best value. This analysis shows that even at US wholesale prices, semaglutide's superior efficacy makes it more cost-effective per successful outcome than older GLP-1 drugs — a finding that supports formulary inclusion and insurance coverage decisions.
The Bigger Picture
Cost-effectiveness analyses like this shape which drugs insurers cover and which ones patients can access. As GLP-1 drugs expand from diabetes into obesity and cardiovascular disease, the value question becomes even more important. This study was part of the evidence package that helped position semaglutide as a preferred GLP-1 drug on many US formularies, contributing to its commercial dominance.
What This Study Doesn't Tell Us
Funded by Novo Nordisk (semaglutide manufacturer), creating potential conflict of interest. Based on wholesale acquisition costs, which don't reflect actual prices paid by patients or insurers after rebates and discounts. The analysis uses clinical trial data which may not reflect real-world effectiveness. US pricing only — results may differ in other markets. Costs from July 2018 are now outdated.
Questions This Raises
- ?How does the cost-effectiveness picture change with net prices (after rebates) rather than wholesale acquisition costs?
- ?Does tirzepatide offer even better cost-of-control given its superior efficacy in head-to-head trials?
- ?Would real-world adherence and discontinuation rates change the cost-effectiveness conclusions?
Trust & Context
- Key Stat:
- Best cost-of-control across all endpoints Despite higher list price, semaglutide's greater efficacy means it costs less per patient who actually reaches blood sugar and weight loss goals compared to exenatide ER and dulaglutide
- Evidence Grade:
- This is a well-structured health economics analysis using data from two rigorous RCTs (SUSTAIN 3 and 7). However, it's industry-funded, uses list prices rather than actual net costs, and the clinical data comes from controlled trial settings that may not reflect real-world performance. Moderate evidence strength.
- Study Age:
- Published in 2019 with July 2018 pricing data. US drug prices and the competitive landscape have changed significantly since then — tirzepatide has entered the market, biosimilars are approaching, and pricing dynamics have shifted. The methodological approach remains valid.
- Original Title:
- A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA.
- Published In:
- Advances in therapy, 36(5), 1190-1199 (2019)
- Authors:
- Johansen, Pierre(2), Hunt, Barnaby(2), Iyer, Neeraj N, Dang-Tan, Tam, Pollock, Richard F
- Database ID:
- RPEP-04263
Evidence Hierarchy
Frequently Asked Questions
What does 'cost of control' mean in this context?
Cost of control divides the annual drug cost by the proportion of patients who reach a treatment target. For example, if a drug costs $10,000/year and 50% of patients reach their goal, the cost of control is $20,000 per successfully treated patient. A drug that costs more per year but gets more patients to goal can still have a lower cost of control.
Does this mean semaglutide is cheaper than other GLP-1 drugs?
Not necessarily cheaper per prescription — but cheaper per patient who actually reaches their blood sugar and weight loss goals. Because semaglutide is more effective at getting patients to treatment targets, you spend less money per successful outcome even if the per-dose price is similar or slightly higher.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-04263APA
Johansen, Pierre; Hunt, Barnaby; Iyer, Neeraj N; Dang-Tan, Tam; Pollock, Richard F. (2019). A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA.. Advances in therapy, 36(5), 1190-1199. https://doi.org/10.1007/s12325-019-00915-8
MLA
Johansen, Pierre, et al. "A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA.." Advances in therapy, 2019. https://doi.org/10.1007/s12325-019-00915-8
RethinkPeptides
RethinkPeptides Research Database. "A Relative Cost of Control Analysis of Once-Weekly Semagluti..." RPEP-04263. Retrieved from https://rethinkpeptides.com/research/johansen-2019-a-relative-cost-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.